Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
Introduction Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-associated mortality globally. Immune-checkpoint blockade (ICB) is one of the systemic therapy options for HCC. However, response rates remain low, necessitating robust predictive biomarkers. In the present study, we e...
Main Authors: | Valerie Chew, Su Pin Choo, Bernett Lee, Sahil Saraf, Harry Ho Man Ng, Ren Yuan Lee, Siting Goh, Isabel Shu Ying Tay, Sherlly Lim, Bijin Au, Josh Jie Hua Loh, John Edward Connolly, Tracy Loh, Wei Qiang Leow, Joycelyn Jie Xin Lee, Fabio Malavasi, Ser Yee Lee, Pierce Chow, Evan W Newell |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-07-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/8/2/e000987.full |
Similar Items
-
Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
by: Hyun Tae Lee, et al.
Published: (2017-07-01) -
Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
by: Hyun Tae Lee, et al.
Published: (2019-03-01) -
Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells
by: Yunlong Zhao, et al.
Published: (2018-07-01) -
PD-L1 Expression and Combined Status of PD-L1/PD-1–Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients
by: Jiheun Han, et al.
Published: (2017-01-01) -
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
by: Xin Wang, et al.
Published: (2019-02-01)